GenSci introduction
1 / 26Páginas

金赛药业 GeneScience Pharmaceutical Co., Ltd.

Changchun High-Tech Industries (Group) Co., Ltd （CCHT)：000661SZ To become a global biopharmaceutical leader in the field of Pediatric and Clinical Pipelines Disease Domains Women's healt

TOP 50 Global Pharmaceutical Companies by Market Capitalization Ranking in 2022 Industry Ranking Johnson & Johnson Novo Nordisk Total Market Cap （USD billions） ······ TOP50 among global listed pharmaceutical companies by market cap① 2022 TOP50 among 2022 Chinese biopharmaceutical enterprises 2022 China Top 100 Pharmaceutical companies by Ministry of Industry and Information Technology 2023 Ranking of Bio-pharmaceutical R&D Strength in China ①CHOICE Database；②MENET Database;③YAOZH Database ; ④Ministry of Industry and Information Technology，MIIT Changchun High-tech Teva Pharmaceutical

Global Layout Dunhua Switzerland Changchun-GenSci Headquarters Shanghai Chongqing R&D Center Commercial Team Production Base

Milestone: Perseverance Over 20 Years 2016 2014 2008 Launch of Jintropin® Powder Launch of Genfulin®, Molgramostim (rhGM-CSF) Topical Gel 2005 Launch of GENFULIN®,GMCSF hydro-gel Launch of PEG-GH 1st Long-Acting GH of world 2015 Launch of JINFOLLIN®, rhFSH Powder 1st in China Launch of GenSci Zengyin Electronic injector for GH 2021 Launch of JINSHUAN® Dienogest tablets Launch of JINSAIJIE® Cetrorelix The Shanghai Innovation and R&D Center was foun

Development Strategy Diversification Building a diversified Business Unit organization Global Innovation and R&D Global leading product pipeline in endocrinology and Women's health. Business Innovation Full-channel and in-depth coverage An ecosystem focusing on a children's health management Child Health Women’s Health Internationalization Developing and launching innovative drugs overseas Developing international business capabilities and business cooperation Focusing on six major Therapeutics Diversified Business Layout Antimicrobial resistance Rheumatology Immunology

Scientific Innovation

Growth Hormone Products Portfolio GenSci stands as the world's sole genetic engineering pharmaceutical company equipped with three generations of growth hormone. We are dedicated to the unwavering enhancement of growth hormone products. Jintropin® Somatropin (rDNA origin) Injection Somatropin (rDNA origin Injection) Polyethylene Glycol Recombinant Human Growth Hormone Injection The first recombinant human growth hormone made in China The first liquid recombinant human growth hormone in Asia Marketed/ Indication Marketed/Indication PGHD Short Bowel Syndrome Short Bowel Severe Burns Severe...

Fueled by Independent Technology Platform, We Create Toptier products with Significant Barriers to Entry Developing a suite of advanced R&D innovation platforms through internal research and external collaboration, with the strategic goal of positioning each marketed product as the exclusive choice in China, among the top 3 globally, or as the bestin-class option with substantial clinical advantages. Innovative Technology Platform for Large Molecule Drug Development Innovative Technology Platform for Small Molecule Drug Development Technology Platform for Special Formulation Development...

Child Health Developing an innovative product line centered around growth, sexual development, childhood obesity, and other major diseases. Candidate Drugs Central Precocious Puberty Long-Acting Microspheres for 1Month Delivery Central Precocious Puberty The only available formulation in China featuring 6 months long-acting Adult Stimulation Test Class 1 Chemical Drug

Women's Health Developing an innovative product line focused on assisted reproduction and menopause management in the field of gynecology. Candidate Drugs Recombinant Human Follicle-Stimulating Hormone for Injection Assisted Reproduction Triptorelin Acetate Injection Hypothalamic GnRH Receptor Assisted Reproduction Cetrorelix Acetate for Injection Pituitary Cell Membrane Receptor Assisted Reproduction Assisted Reproduction Long-Acting Weekly Formulation Dienogest Tablets Progesterone Receptor Progesterone supplementation First Generic in China Stress Urinary Incontinence Class 1 Chemical...

Rheumatology Immunology Creating an innovative product line focused on gout and autoimmune diseases. Candidate Drugs Acute Gouty Arthritis Class 1 Biological Drug Systemic Juvenile Idiopathic Arthritis Class 1 Biological Drug Interstitial Lung Disease Associated with Hoof Tissue Class 1 Biological Drug

Dermatology Developing an innovative product line focused on skin diseases such as autoimmune conditions, and skin beauty. Candidate Drugs Recombinant Human GranulocyteMacrophage Colony Stimulating Factor (GM-CSF) Hydro-gel Wound Healing, Used for —— Deep Second-Degree Burn Wounds

Oncology Innovation product line development around tumors such as prostate cancer, gastric cancer, and colorectal cancer Candidate Drugs Prostate Cancer The only available formulation in China featuring 6 months long-acting Gastric Cancer Class 1 Biological Drug Breast Cancer Class 1 Chemical Drug

Candidate Drugs Risperidone Transdermal Patch Alzheimer's Disease Marketed, Exclusive Formulation in China Lidocaine and Prilocaine Cream Surface Analgesia, —— Epidermal Anesthesia (Premature Ejaculation)

Shanghai R&D Center Is Under Construction

Manufacturing Capabilities Chemical drugs and microsphere products Gel products Growth hormone Follicle-stimulating hormone Special formulation production base Antibody products PEG raw materials Raw materials for chemical drugs and Hormone preparation Highly active product Preparations Chemical drugs Industrial Park Pilot plant for chemical drugs and API Large-scale antibody production base Next-generation Growth Hormone Industrial Park growth hormone Changchun International Pharmaceutical Industry Park

A Comprehensive Industrialization Platform Tailored to Fulfill Future Capacity Expansion Needs and Global Supply Demands Cell culture capacity Cartridge bottles: 72 million, 30 million (in planning and construction) Ampoules: 72 million, 30 million (in planning and construction) Prefilled syringe: 15 million, 30 million (in planning and construction) Special chemotherapy formulations (microspheres): 1.2 million Prokaryotic fermentation production capacity Polymer raw material production capacity 2.5T Production capacity of raw material and auxiliary material for chemical drugs Production...